QURE
uniQure N.V.
Nasdaq · usd
uniQure N.V. (QURE) trades at $19.35 (-4.35%) as of 7:30:06 PM EST on Nov 20, 2026, -16.27% over the past month. Market cap is $1.42B, with 6.4 days to cover in short interest.
Stock performance
How uniQure N.V. (QURE) stock has performed from one day to one year, with its 52-week range.
- 1D
- -4.35%
- 1W
- -18.73%
- 1M
- -16.27%
- YTD
- -19.14%
- 1Y
- -30.42%
- 52-wk range
- $8.73 – $51.72
Key statistics
Today's trading snapshot for QURE: day range, open, previous close, volume and market cap.
- Day range
- $19.00 – $21.60
- Open
- $19.82
- Prev close
- $20.23
- Volume
- 2.1M
- Market cap
- $1.42B
- Shares out
- 70.14M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for uniQure N.V.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 70.36
- P/B
- 4.82
- P/FCF
- —
- ROE
- -79.0%
- ROA
- -24.8%
- Debt/Equity
- 0.17
- Div yield
- 0.00%
As of Nov 19, 2026
8-K filings
Material corporate events uniQure N.V. has disclosed to the SEC on Form 8-K.
- Quarterly earningsNov 4, 2026
On November 4, 2026, uniQure N.V. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update.
- Clinical trial resultsNov 2, 2026
“The BLA is supported by the previously announced 36-month data analysis from the Phase I/II clinical study of ifezuntirgene inilparvovec, compared to a propensity score-matched external control derived from the Enroll-HD natural history database.”
- Investor presentationSep 29, 2026
“On September 29, 2026, uniQure N.V. (the "Company") presented an update of its ongoing clinical trials of AMT-130 (the "Presentation") and issued a press release which summarizes the Presentation (the "Release").”
- Public offeringJun 24, 2026
On June 23, 2026, uniQure N.V. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Leerink Partners LLC, as representative of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of 4,945,055 of the Company's ordinary shares (the "Firm Shares"), at a price to the public of $45.50 per ordinary share.
- Clinical trial resultsJun 22, 2026
As of the May 29, 2026 data cutoff date, three of six patients in the first, low-dose cohort (1x1012 gc/mL) achieved meaningful reductions in disabling seizures during months four through six of follow-up, ranging from a 79% to 100% decline from baseline. The remaining three patients in the low-dose cohort experienced variable changes in disabling seizures during months four through six of follow-up, ranging from a 33% decrease to a 36% increase compared to baseline. As of June 19, 2026, there have been no serious adverse events related to AMT-260 or the surgical procedure reported. All reported adverse events in the low dose cohort were classified as mild or moderate in severity, with the most common adverse event being headache (N=2).
QURE short interest
How heavily QURE is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 6.4
- Short interest
- 8.51M
- Avg volume
- 1.33M
As of · reported to FINRA twice monthly.
QURE news
The latest news and headlines about uniQure N.V. (QURE).
- QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?neutralZacks Investment Research· Nov 13, 2026
- 3 Promising Genomics Stocks to Add to Your Portfolio NowpositiveZacks Investment Research· Oct 30, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ClearPoint Neuro, Inc. - CLPTnegativeGlobeNewswire Inc.· Oct 13, 2026
- UNIQURE INVESTIGATION: QURE Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsnegativeGlobeNewswire Inc.· Sep 30, 2026
- uniQure Plunges on Additional Data From Huntington's Disease StudynegativeZacks Investment Research· Sep 30, 2026
Frequently asked questions
What is the uniQure N.V. (QURE) stock price today?
uniQure N.V. (QURE) is trading at $19.35 (-4.35% on the day) as of 7:30:06 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is uniQure N.V.?
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases.
What is the short interest in QURE?
As of Oct 30, 2026, QURE has 8.51M shares short and 6.4 days to cover.
What exchange is QURE listed on?
uniQure N.V. (QURE) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of QURE with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a QURE analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.